• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

妇科肿瘤个性化医疗时代的曙光

The Dawning of the Age of Personalized Medicine in Gynecologic Oncology.

作者信息

Leslie Kimberly K, Thiel Kristina W, Benbrook Doris M, Mutch David

机构信息

Department of Obstetrics and Gynecology and the Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics, Iowa City, IA 52242, USA.

Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.

出版信息

Cancers (Basel). 2020 Oct 27;12(11):3135. doi: 10.3390/cancers12113135.

DOI:10.3390/cancers12113135
PMID:33120871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7693675/
Abstract

It is an undeniable truth that every patient with cancer is unique. [...].

摘要

每个癌症患者都是独特的，这是一个不可否认的事实。[……]

相似文献

1
The Dawning of the Age of Personalized Medicine in Gynecologic Oncology.妇科肿瘤个性化医疗时代的曙光
Cancers (Basel). 2020 Oct 27;12(11):3135. doi: 10.3390/cancers12113135.
2
Personalized Medicine in Gynecologic Cancer: Fact or Fiction?妇科癌症的个体化医学：事实还是虚构？
Surg Oncol Clin N Am. 2020 Jan;29(1):105-113. doi: 10.1016/j.soc.2019.08.008.
3
Personalized Medicine in Gynecologic Cancer: Fact or Fiction?妇科肿瘤的个体化医学：事实还是虚构？
Obstet Gynecol Clin North Am. 2019 Mar;46(1):155-163. doi: 10.1016/j.ogc.2018.09.010.
4
Palliative Care Education in Gynecologic Oncology: a Survey of Gynecologic Oncologists and Gynecologic Oncology Fellows in Thailand.妇科肿瘤学中的姑息治疗教育：泰国妇科肿瘤学家和妇科肿瘤学研究员的一项调查
Asian Pac J Cancer Prev. 2015;16(15):6331-4. doi: 10.7314/apjcp.2015.16.15.6331.
5
Integrating a complementary medicine consultation for women undergoing chemotherapy.为接受化疗的女性提供补充医学咨询服务。
Int J Gynaecol Obstet. 2014 Jan;124(1):51-4. doi: 10.1016/j.ijgo.2013.07.019. Epub 2013 Oct 5.
6
Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital.为大型医院的妇科肿瘤患者构建个性化医疗基础设施。
J Pers Med. 2021 Dec 21;12(1):3. doi: 10.3390/jpm12010003.
7
Gynecologic Oncology in the Department of Defense.国防部妇科肿瘤学。
Semin Reprod Med. 2019 Sep;37(5-06):222-226. doi: 10.1055/s-0040-1709706. Epub 2020 May 1.
8
The dawning era of personalized medicine exposes a gap in medical education.个性化医疗的崭新时代暴露了医学教育中的一个差距。
PLoS Med. 2009 Aug;6(8):e1000138. doi: 10.1371/journal.pmed.1000138. Epub 2009 Aug 25.
9
Personalized oncology: recent advances and future challenges.个性化肿瘤学：最新进展与未来挑战。
Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19.
10
Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice.提高妇科肿瘤护理质量并降低成本。妇科肿瘤学会临床实践建议。
Gynecol Oncol. 2015 May;137(2):280-4. doi: 10.1016/j.ygyno.2015.02.021. Epub 2015 Feb 28.

引用本文的文献

1
Differences in single gene expression patterns and signaling pathways between Black and White patients in high grade endometrioid endometrial cancer independent of BMI.高级别子宫内膜样子宫内膜癌中，黑人与白人患者单基因表达模式和信号通路的差异，与体重指数无关。
Gynecol Oncol Rep. 2024 Mar 6;52:101360. doi: 10.1016/j.gore.2024.101360. eCollection 2024 Apr.
2
Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing.成功建立用于疾病建模和药物敏感性测试的妇科癌症患者来源类器官培养体系。
Cancers (Basel). 2021 Jun 10;13(12):2901. doi: 10.3390/cancers13122901.

本文引用的文献

1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.奥拉帕利联合贝伐珠单抗作为卵巢癌一线维持治疗。
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
2
Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.免疫疗法：林奇相关妇科癌症的检查点抑制剂。
Curr Treat Options Oncol. 2019 Aug 23;20(10):75. doi: 10.1007/s11864-019-0676-8.
3
PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.BRCA 野生型卵巢癌的 PARP 抑制剂；基因改变、同源重组缺陷和联合治疗。
Jpn J Clin Oncol. 2019 Aug 1;49(8):703-707. doi: 10.1093/jjco/hyz090.
4
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌患者：一项多中心、开放标签、单臂、2 期临床试验的中期分析。
Lancet Oncol. 2019 May;20(5):711-718. doi: 10.1016/S1470-2045(19)30020-8. Epub 2019 Mar 25.
5
Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas.对来自癌症基因组图谱的卵巢癌数据集的临床和化疗结果进行重新注释与分析。
JCO Clin Cancer Inform. 2018 Dec;2:1-16. doi: 10.1200/CCI.17.00096.
6
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.奥拉帕利维持治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
7
Mechanisms of PARP inhibitor sensitivity and resistance.聚腺苷二磷酸核糖聚合酶抑制剂敏感性和耐药性的机制。
DNA Repair (Amst). 2018 Nov;71:172-176. doi: 10.1016/j.dnarep.2018.08.021. Epub 2018 Aug 23.
8
Endocrine therapy in ovarian cancer: where do we stand?卵巢癌的内分泌治疗：我们目前的进展如何？
Curr Opin Obstet Gynecol. 2018 Feb;30(1):17-22. doi: 10.1097/GCO.0000000000000423.
9
Immunotherapy in Gynecologic Cancers: Are We There Yet?妇科癌症的免疫治疗：我们成功了吗？
Curr Treat Options Oncol. 2017 Aug 24;18(10):59. doi: 10.1007/s11864-017-0504-y.
10
Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature.卵巢癌的靶向治疗。文献的全面系统综述。
Anticancer Res. 2017 Jun;37(6):2809-2815. doi: 10.21873/anticanres.11631.